Evotec: US Unit Gets $49.9 Mln Antibodies Contract From U.S. Department Of Defense

German drug maker Evotec SE (EVTCY.PK,EVOTF.PK) announced Tuesday that its Seattle-based unit, Just - Evotec Biologics, Inc., has received a contract from the U.S. Department of Defense or DOD valued up to $ 49.9 million for the rapid development of monoclonal antibody or mAb-based drug product prototypes targeting plague.

Under the DOD's Accelerated Antibodies Program, Plague, an infectious disease caused by the bacterium Yersinia pestis or Y. pestis, is one of the designated targets of interest.

Under the contract, Just - Evotec Biologics will develop mAb-based drug product prototype(s) from sequence discovery or evaluation of existing mAbs to completion of Phase I first-in-human or FIH clinical trials.

Just - Evotec Biologics will leverage its data-driven, highly automated end-to-end biologics technology platform, J.DESIGN, that includes; antibody discovery, molecular optimisation, cell line and process development.

The company will also provide pre-clinical and clinical capabilities for mAb prophylactic approvals.

Just - Evotec Biologics' J.POD Redmond, Washington biologics development and cGMP manufacturing facility will develop mAb-based drug products for the US DOD.

According to the company, the rapid, cost-efficient development of mAb product protypes will yield an accelerated supply of safe and efficacious mAb medical counter measures or MCMs for use against plague.

Bruce Goodwin, Joint Project Lead for CBRND Enabling Biotechnologies, said, "JPEO-CBRND-EB is pleased to work with Just/Evotec on this innovative and significant program to protect the Warfighter. Just/Evotec brings a unique approach, a robust toolset and deep expertise to address a challenging threat in a highly accelerated time frame."

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Juul Labs, an e-cigarette maker, said it has reached settlements with more than 5,000 vaping lawsuits in the United States. The cases were related to personal injury, consumer class action, government entity, and Native American tribes. In a statement, the company said it cannot disclose the settlement amount at this time as part of the settlement and court process. Apple Inc. plans to start using American-made processors from the new advanced chip factory in Phoenix, Arizona operated by chip giant Taiwan Semiconductor Manufacturing Co., according to its Chief Executive Officer Tim Cook. At an event in the factory in Arizona, which was attended by U.S. President Joe Biden, it was also announced that TSMC will invest $40 billion in the new factory. Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965.
Follow RTT